生物医药系列产品
数据
资源
版本对比
免费注册
预约演示
免费注册
Chronic Kidney Disease (CKD)
Pipeline Insight, 2020 Report Featuring 55 Key players & 10 Key Products
2021-01-05
·
GlobeNewswire
小分子药物
并购
合作
Dublin, Dec. 31, 2020 (GLOBE NEWSWIRE) -- The "
Chronic Kidney Disease (CKD)
- Pipeline Insight, 2020" drug pipelines has been added to ResearchAndMarkets.com's offering. The "
Chronic Kidney Disease (CKD)
- Pipeline Insight, 2020," report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in
Chronic Kidney Disease
pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Chronic Kidney Disease Emerging Drugs Chapters This segment of the
Chronic Kidney Disease
report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Chronic Kidney Disease
Emerging Drugs
AZD5718
:
AstraZeneca
AstraZeneca
is conducting a study to evaluate the dose-response efficacy, safety, and pharmacokinetics (PK) of
AZD5718
in participants with
proteinuric chronic kidney disease
. The study will be conducted in approximately 118 study centers across 12 countries. The overall study period will be around 28 weeks. Approximately 632 participants comprising of 67%
diabetic kidney disease (DKD)
and 33% non-DKD participants will be enrolled. DDO-3055:
Jiangsu HengRui Medicine Co., Ltd.
Jiangsu
HengRui Medicine
is conducting a randomized, double-blind, dose-escalating, placebo controlled, phase I study to evaluate the safety and pharmacokinetics and pharmacodynamics of
DDO-3055
in healthy volunteers and patients with
Chronic Kidney Disease
. This is a randomized, double-blind, dose-escalating, placebo controlled, Phase I study to evaluate the safety, pharmacokinetics and pharmacodynamics of
DDO-3055
in healthy volunteers and patients with
chronic kidney disease
. 48 healthy volunteers will be enrolled in Part A, and 18 patients with
chronic kidney disease
will be enrolled in Part B.
Chronic Kidney Disease
: Therapeutic Assessment This segment of the report provides insights about the different
Chronic Kidney Disease
drugs segregated based on following parameters that define the scope of the report, such as: Major Players in
Chronic Kidney Disease
There are approx. 50+ key companies which are developing the therapies for
Chronic Kidney Disease
. The companies which have their
Chronic Kidney Disease
drug candidates in the mid to advanced stage, i.e. phase III and Phase II include,
AstraZeneca
,
UnicoCell Biomed
,
Jiangsu Hansoh Pharmaceutical
, Bio Sidus,
Keryx Biopharmaceuticals
,
AMAG Pharmaceuticals
,
inRegen
,
AbbVie
etc. Phases The report covers around 50+ products under different phases of clinical development like Mid-stage products (Phase II and Phase I/II) Early-stage products (Phase I/II and Phase I) along with the details of Pre-clinical and Discovery stage candidates Discontinued & Inactive candidates Route of
Administration
Chronic Kidney Disease
pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as Subcutaneous Intravenous Oral Intramuscular Molecule Type Products have been categorized under various Molecule types such as Small molecules Proteins and peptides Polymers Diamines Chlorinated hydrocarbons Product Type Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Chronic Kidney Disease
: Pipeline Development Activities The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses
Chronic Kidney Disease
therapeutic drugs key players involved in developing key drugs. Pipeline Development Activities The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging
Chronic Kidney Disease
drugs. Report Highlights The companies and academics are working to assess challenges and seek opportunities that could influence
Chronic Kidney Disease
R&D. The therapies under development are focused on novel approaches to treat/improve
Chronic Kidney Disease
. August 2020: DAPA-
CKD
trial meets primary endpoint in patients with
chronic kidney disease
.
Dapagliflozin
reduces the risk of
kidney failure
, death from cardiovascular causes or heart failure hospitalisation and all-cause mortality in
chronic kidney disease
patients with or without
type 2 diabetes
. That's the main result of the DAPA-
CKD
trial presented in a Hot Line session today at ESC Congress 2020.
Chronic Kidney Disease
Report Insights
Chronic Kidney Disease
Pipeline Analysis Therapeutic Assessment Unmet Needs Impact of Drugs
Chronic Kidney Disease
Report Assessment Pipeline Product Profiles Therapeutic Assessment Pipeline Assessment Inactive drugs assessment Unmet Needs Key Questions Current Treatment Scenario and Emerging Therapies: How many companies are developing
Chronic Kidney Disease
drugs? How many
Chronic Kidney Disease
drugs are developed by each company? How many emerging drugs are in mid-stage, and late-stage of development for the treatment of
Chronic Kidney Disease
? What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the
Chronic Kidney Disease
therapeutics? What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies? What are the clinical studies going on for
Chronic Kidney Disease
and their status? What are the key designations that have been granted to the emerging drugs?
Key Players
AdAlta Ltd
Allena Pharmaceuticals Inc
apceth Biopharma GmbH
Arch Biopartners Inc
Astellas Pharma Inc
AstraZeneca Plc
Bayer AG
BiOrion Technologies BV
Boehringer Ingelheim GmbH
Boryung Pharmaceutical Co Ltd
Celgene Corp
Certa Therapeutics Pty Ltd
Conatus Pharmaceuticals Inc
Corvidia Therapeutics Inc
DiaMedica Therapeutics Inc
Dimerix Bioscience Pty Ltd
DiscoveryBiomed Inc
DURECT Corp
Epigen Biosciences Inc
Galectin Therapeutics Inc
GenKyoTex SA
GNI Group Ltd
iBio Inc
IC-MedTech Inc
Ipsen SA
Isarna Therapeutics GmbH
KBP BioSciences Co Ltd
Kidney Fibrosis
Klotho Therapeutics Inc
Les Laboratoires Servier SAS
ManRos Therapeutics
Mironid Ltd
NovaTarg Therapeutics Inc
Novo Nordisk AS
OPKO Health Inc
Opsidio LLC
Otsuka Holdings Co Ltd
Pharmaxis Ltd
Q BioMed Inc
Redx Pharma Plc
Regulus Therapeutics Inc
Resverlogix Corp
Sanwa Kagaku Kenkyusho Co Ltd
Sarfez Pharmaceuticals Inc
Scholar Rock Inc
Sirnaomics Inc
Sphaera Pharma Pte Ltd
Symic Biomedical Inc
Taisho Pharmaceutical Holdings Co Ltd
Theravance Biopharma Inc
Unity Biotechnology Inc
Vascular Biogenics Ltd
Vascular BioSciences
VESSL
Therapeutics Ltd
Vicore Pharma AB
Key Products
AZD5718
MEDI8367
efepoetin alfa Verinurad
Empagliflozin
DDO-3055 KBP-5074
Doxercalciferol TRC101
Pegol-Sihematide
For more information about this drug pipelines report visit Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research. CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
机构
麗彤生醫科技股份有限公司
Otsuka Holdings Co., Ltd.
AMAG Pharmaceuticals, Inc.
[+60]
适应症
慢性肾病
糖尿病肾病
肾功能不全
[+2]
靶点
-
药物
Atuliflapon
DDO-3055
达格列净
[+4]
标准版
¥
16800
元/账号/年
新药情报库 | 省钱又好用!
立即使用
来和芽仔聊天吧
热门报告
特应性皮炎深度解析:药物开发、专利分析与风险评估
智慧芽生物医药
2024年7月全球首批及特殊审评药物报告
智慧芽生物医药
GPRC5D靶点专利调研报告
智慧芽生物医药
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台,助您全方位提升您的研发与决策效率。
开始免费试用
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台,以API或者数据包形式对外开放,助您更加充分利用智慧芽新药情报信息。
试用数据服务